HomeCompareSMEBF vs ABBV

SMEBF vs ABBV: Dividend Comparison 2026

SMEBF yields 5.63% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SMEBF wins by $411.8K in total portfolio value· pulled ahead in Year 2
10 years
SMEBF
SMEBF
● Live price
5.63%
Share price
$0.56
Annual div
$0.03
5Y div CAGR
44.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$514.2K
Annual income
$276,115.16
Full SMEBF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SMEBF vs ABBV

📍 SMEBF pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSMEBFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SMEBF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SMEBF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SMEBF
Annual income on $10K today (after 15% tax)
$478.61/yr
After 10yr DRIP, annual income (after tax)
$234,697.89/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, SMEBF beats the other by $213,641.88/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SMEBF + ABBV for your $10,000?

SMEBF: 50%ABBV: 50%
100% ABBV50/50100% SMEBF
Portfolio after 10yr
$308.3K
Annual income
$150,443.46/yr
Blended yield
48.80%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SMEBF
No analyst data
Altman Z
2.6
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SMEBF buys
0
ABBV buys
0
No recent congressional trades found for SMEBF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSMEBFABBV
Forward yield5.63%3.06%
Annual dividend / share$0.03$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR44.8%40.6%
Portfolio after 10y$514.2K$102.3K
Annual income after 10y$276,115.16$24,771.77
Total dividends collected$466.3K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SMEBF vs ABBV ($10,000, DRIP)

YearSMEBF PortfolioSMEBF Income/yrABBV PortfolioABBV Income/yrGap
1$11,515$815.33$11,550$430.00$35.00ABBV
2← crossover$13,592$1,270.55$13,472$627.96+$120.00SMEBF
3$16,573$2,029.47$15,906$926.08+$667.00SMEBF
4$21,082$3,348.76$19,071$1,382.55+$2.0KSMEBF
5$28,322$5,764.71$23,302$2,095.81+$5.0KSMEBF
6$40,785$10,480.51$29,150$3,237.93+$11.6KSMEBF
7$64,064$20,424.13$37,536$5,121.41+$26.5KSMEBF
8$111,964$43,415.18$50,079$8,338.38+$61.9KSMEBF
9$222,482$102,680.67$69,753$14,065.80+$152.7KSMEBF
10$514,171$276,115.16$102,337$24,771.77+$411.8KSMEBF

SMEBF vs ABBV: Complete Analysis 2026

SMEBFStock

Sime Darby Berhad, an investment holding company, operates in the industrial, motors, logistics, healthcare, and other businesses in Malaysia and internationally. The company manufactures, assembles, and sells generators, and agricultural and industrial machineries; markets, installs, rents, and services security products; markets and installs electronic and electro-mechanical equipment, instruments, and systems integration; sells, rents, and assembles Caterpillar equipment and spare parts; reconditions used equipment and machineries; supplies global positioning systems/digital work site positioning, and machine control products for heavy and highway construction applications; sells lift trucks and spare parts, and services other material handling equipment; imports and sells technical, nautical, and scientific instruments, as well as mechanical, electrical, and electronic equipment; and sells, hires, and services survey and marine equipment. It also provides heat exchangers, radiators, process equipment modules, filters, and separators; training and security services; and consultancy and other services for installation, operation, repair, and maintenance of industrial machines, equipment, and vehicles. In addition, the company manufactures, sells, and distributes passenger and light commercial vehicles, and spare parts; imports and distributes motor vehicles; offers vehicle rental services; and engages in general investment activities. Further, it provides port and warehousing services; tugboat pilot, container, property management, and childcare services; and owns and manages logistics parks. Additionally, the company operates hospitals; provides insurance and reinsurance brokerage, and advisory services; and sells Trimble technical solutions, as well as provides engineering, procurement, construction, installation, hook-up, and commissioning services related to oil and gas industry. Sime Darby Berhad was founded in 1910 and is based in Petaling Jaya, Malaysia.

Full SMEBF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SMEBF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SMEBF vs SCHDSMEBF vs JEPISMEBF vs OSMEBF vs KOSMEBF vs MAINSMEBF vs JNJSMEBF vs MRKSMEBF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.